Manufacturer record

Orison Pharma International Khari: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

8 batches manufactured by Orison Pharma International Khari (Himachal Pradesh) were declared Not of Standard Quality between April 2020 and June 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

8 records linked to Orison Pharma International Khari in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
8Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Apr 2020 to Jun 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

8
NSQ batches since 2020
8
Products affected
Description
Most common failure
Jun 2026
Latest alert

Flagged batches per year

2020 · 12024 · 22025 · 42026 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
AzithromycinTablets IP 25I-T1749Mfg 2025-12 · Exp 2027-11 Test for Uniformity of Weight of TabletsUniformity of weight/content RDTL, Bellary, KarnatakaState lab Jun 2026
Paracetamol Tablets IP 650 mg Arvimol 650 Tablets 24I-T1956EMfg 2024-12 · Exp 2026-11 The sample is not of standard quality for The reason stated under Description of The tablets.Description RDTL, GuwahatiCDSCO lab Dec 2025
Opivas 10 tablets 23C-T465Mfg 2023-06 · Exp 2025-05 The sample does not comply with IP requirements for Dissolution test.Dissolution CDTL MumbaiCDSCO lab Apr 2025
Opirin-75 Tablets (Aspirin Tablets IP 75mg) 23G-T1526Mfg 2023-10 · Exp 2025-09 The sample does not comply for description as, almost all the tablets are brittle in nature with rough surface.Description State Lab MaharashtraState lab Apr 2025
Opirin-75 Tablets (Aspirin Tablets IP 75mg) 23K-T2727Mfg 2024-02 · Exp 2026-01 The sample does not comply for description as, the tablets shows uneven light brown coloured spots on the surface of almost all the tablets.Description State Lab MaharashtraState lab Apr 2025
FERRIMACK-XT Tablets, Ferrous Ascorbate, Folic Acid & Zinc Tablets 23C-C081Mfg 2023-06 · Exp 2025-05 NOT OF STANDARD QUALITY The sample does not meet the criteria for uniformity of weight as per IP. out of 20 capsules weighed, 11 capsules deviates the 10 percent limit as per IP and from that 3 capsules are under double deviation. Hence, Sample does not meet the specifications wrt. Uniformity of Weight of Capsules as per IP.Uniformity of weight/content State Lab Drugs Control Laboratory, TelanganaState lab Nov 2024
Sodium Valproate and Valproic Acid Controlled-Release Tablets 200 mg (Opi Soproate - 200) 23E-T990Mfg 2023-08 · Exp 2025-07 Average weight, Dissolution & DescriptionDissolution CDTL MumbaiCDSCO lab Mar 2024
Levocetirizine Hydrochloride Tablets I.P. (ALECET) 18H-T1108HMfg 2018-11 · Exp 2020-10 AssayAssay RDTL GuwahatiState lab Apr 2020

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.